28 July 2017Americas

Federal Circuit affirms ruling on Regeneron inequitable conduct

The US Court of Appeals for the Federal Circuit has affirmed a ruling of a lower court that found a patent owned by Regeneron unenforceable because of the biotech company’s inequitable conduct.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 January 2018   The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.

More on this story

Americas
2 January 2018   The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.

More on this story

Americas
2 January 2018   The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.